Safety and efficacy of neoadjuvant chemoradiotherapy with moderately hypofractionated intensity‐modulated radiotherapy for resectable pancreatic cancer: A prospective, open‐label, phase II study

BACKGROUND: Resectable pancreatic cancer (RPC) is potentially resectable on admission, and the impact of neoadjuvant therapy on these tumors is controversial. Moreover, the safety and efficacy of neoadjuvant chemoradiotherapy with moderately hypofractionated intensity‐modulated radiation therapy (NA...

ver descrição completa

Detalhes bibliográficos
Autores principales: Masui, Toshihiko, Nagai, Kazuyuki, Anazawa, Takayuki, Kasai, Yosuke, Yogo, Akitada, Yoshimura, Michio, Mizowaki, Takashi, Uza, Norimitsu, Fukuda, Akihisa, Matsumoto, Shigemi, Kanai, Masashi, Isoda, Hiroyoshi, Kawaguchi, Yoshiya, Uemoto, Shinji, Hatano, Etsuro
Formato: Online Artigo Texto
Idioma:English
Publicado em: John Wiley and Sons Inc. 2023
Assuntos:
RESEARCH ARTICLES
Acesso em linha:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557863/
https://www.ncbi.nlm.nih.gov/pubmed/37649318
http://dx.doi.org/10.1002/cam4.6470

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557863/
https://www.ncbi.nlm.nih.gov/pubmed/37649318
http://dx.doi.org/10.1002/cam4.6470

Registos relacionados